Ubrigene

Suzhou, China · Founded 2015 · Privately Held (backing)

Provider of gene and cell therapy contract research services intended to assist drug development companies. Ubrigene is based in Suzhou, China and was founded in 2015. Its last reported valuation was $50.8 million in Dec 2020. It has raised $143 million.

Last reported valuation
$50.8M
Oct 2026
Priced at
—
Total raised
$142.9M
Last round
—

Who backs Ubrigene?

18 investors
InvestorType
Addor CapitalOther
Cowin CapitalVenture capital
IDG CapitalVenture capital
Guotai Junan Innovation InvestmentVenture capital
Chiron VenturesOther
BGI Co-Win—
Beijing FOF Capital—
CITIC Jingshi Investment—
CLSA Capital Partners—
Finnova Capital—
+ 8 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Ubrigene investors

18 investors are on record for Ubrigene, including Addor Capital, Cowin Capital, IDG Capital and Guotai Junan Innovation Investment.

Free account
More of Ubrigene with a free account
  • ·The complete investor list: 18 names
  • ·Watch Ubrigene: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 18 firms already write checks for companies like Ubrigene. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View